Login to Your Account

Cytokinetics Inc. is suspending development of its lead candidate, tirasemtiv, for ALS after it failed to hit both primary and secondary endpoints in a crucial phase III test.

LONDON – "For the past year and half we have been living with uncertainty. We can now take practical action to maintain business continuity." So said Guido Rasi, executive director of the EMA, giving his reaction to the political decision to move the agency from London to Amsterdam.

Bayer AG is betting up to $1.11 billion (¥124.5 billion) that Peptidream Inc.'s popular therapeutic peptide discovery platform will help it discover novel lead structures in areas such as cancer and cardiology.

More Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: